Similar articles

• Extended experience of neo-adjuvant M-VAC chemotherapy for T1-4 N0 M0 transitional cell carcinoma of the urinary bladder.

  Keating JP, Zincke H, Hahn RG, Morgan WR. Keating JP, et al. Prog Clin Biol Res. 1990;353:119-27. Prog Clin Biol Res. 1990. PMID: 2217409 No abstract available.
• Impact of methotrexate, vinblastine, adriamycin, and cisplatin chemotherapy in patients with lymph node metastases from transitional cell carcinoma of the lower urinary tract.

  Koch MO, Coussens D. Koch MO, et al. Semin Urol. 1993 Feb;11(1):14-9. Semin Urol. 1993. PMID: 8465122 Review. No abstract available.
• [Systemic chemotherapy of urothelial cancer].

  Wolff JM, Jakse G. Wolff JM, et al. Urologe A. 1992 May;31(3):W19-24. Urologe A. 1992. PMID: 1615589 German. No abstract available.
• [Conservative treatment with chemotherapy and radiotherapy in bladder cancer invading the muscle: preliminary results of a prospective study].

  Zapatero A, Pinar B, Arellano R, López M, Marín A, Jiménez U, Pérez Torrubia A. Zapatero A, et al. Arch Esp Urol. 1997 Jun;50(5):448-54; discussion 454-6. Arch Esp Urol. 1997. PMID: 9382586 Spanish.
• [Adjuvant polychemotherapy after radical cystectomy of metastatic bladder cancer].

  Stöckle M. Stöckle M. Urologe A. 1994 Nov;33(6):568-75. Urologe A. 1994. PMID: 7817458 Review. German.